Search Results - "Greaves, Wayne"

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study by Roth, David, Dr, Nelson, David R, MD, Bruchfeld, Annette, MD, Liapakis, AnnMarie, MD, Silva, Marcelo, MD, Monsour, Howard, MD, Martin, Paul, MD, Pol, Stanislas, MD, Londoño, Maria-Carlota, MD, Hassanein, Tarek, MD, Zamor, Philippe J, MD, Zuckerman, Eli, MD, Wan, Shuyan, PhD, Jackson, Beth, MLAS, Nguyen, Bach-Yen, MD, Robertson, Michael, MD, Barr, Eliav, MD, Wahl, Janice, MD, Greaves, Wayne, MD

“…Summary Background Chronic hepatitis C virus (HCV) infection in patients with stage 4–5 chronic kidney disease increases the risk of death and renal graft…”
Get full text

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211 by Gulick, Roy M., Su, Zhaohui, Flexner, Charles, Hughes, Michael D., Skolnik, Paul R., Wilkin, Timothy J., Gross, Robert, Krambrink, Amy, Coakley, Eoin, Greaves, Wayne L., Zolopa, Andrew, Reichman, Richard, Godfrey, Catherine, Hirsch, Martin, Kuritzkes, Daniel R.

“…Background. Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study. Methods. The present study was a…”
Get full text

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial by Sulkowski, Mark, Prof, Pol, Stanislas, Prof, Mallolas, Josep, MD, Fainboim, Hugo, MD, Cooper, Curtis, MD, Slim, Jihad, MD, Rivero, Antonio, MD, Mak, Carmen, PhD, Thompson, Seth, PhD, Howe, Anita YM, PhD, Wenning, Larissa, PhD, Sklar, Peter, MD, Wahl, Janice, MD, Greaves, Wayne, Dr

“…Summary Background Rates of sustained virological response (SVR) to peginterferon–ribavirin are low in patients with hepatitis C virus (HCV) genotype 1 and…”
Get full text

Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy by Shamsuddin, Hala, Raudenbush, Casey L, Sciba, Brittany L, Zhou, Yun-Ping, Mast, T Christopher, Greaves, Wayne L, Hanna, George J, Leong, Ronald, Straus, Walter

“…OBJECTIVE:To evaluate the risk of neural tube defects (NTDs) after exposure to raltegravir during pregnancy. METHODS:Exposures to raltegravir during pregnancy…”
Get full text

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo by Tsibris, Athe M N, Korber, Bette, Arnaout, Ramy, Russ, Carsten, Lo, Chien-Chi, Leitner, Thomas, Gaschen, Brian, Theiler, James, Paredes, Roger, Su, Zhaohui, Hughes, Michael D, Gulick, Roy M, Greaves, Wayne, Coakley, Eoin, Flexner, Charles, Nusbaum, Chad, Kuritzkes, Daniel R

“…High-throughput sequencing platforms provide an approach for detecting rare HIV-1 variants and documenting more fully quasispecies diversity. We applied this…”
Get full text

Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre‐existing renal disease by Reddy, K. Rajender, Roth, David, Bruchfeld, Annette, Hwang, Peggy, Haber, Barbara, Robertson, Michael N., Barr, Eliav, Greaves, Wayne

“…Aim Treatment options have been limited for patients with hepatitis C virus (HCV) infection and chronic kidney disease stage 4/5 (CKD 4/5). The aim of this…”
Get full text

Response to Vicriviroc in Treatment-Experienced Subjects, as Determined by an Enhanced-Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211 by Su, Zhaohui, Gulick, Roy M., Krambrink, Amy, Coakley, Eoin, Hughes, Michael D., Han, Dong, Flexner, Charles, Wilkin, Timothy J., Skolnik, Paul R., Greaves, Wayne L., Kuritzkes, Daniel R., Reeves, Jacqueline D.

“…The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study entry for 118…”
Get full text

HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211 by Wilkin, Timothy J., Su, Zhaohui, Kuritzkes, Daniel R., Hughes, Michael, Flexner, Charles, Gross, Robert, Coakley, Eoin, Greaves, Wayne, Godfrey, Catherine, Skolnik, Paul R., Timpone, Joseph, Rodriguez, Benigno, Gulick, Roy M.

“…Background. Chemokine coreceptor use impacts both the natural history of human immunodeficiency virus type 1 (HIV-1) disease and the potential use of a new…”
Get full text

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject by TSIBRIS, Athe M. N, SAGAR, Manish, COAKLEY, Eoin, KURITZKES, Daniel R, GULICK, Roy M, ZHAOHUI SU, HUGHES, Michael, GREAVES, Wayne, SUBRAMANIAN, Mani, FLEXNER, Charles, GIGUEL, Francoise, LEOPOLD, Kay E

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

A Multicenter Randomized Trial Evaluating Posaconazole versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects with HIV/AIDS by Vazquez, Jose A., Skiest, Daniel J., Nieto, Leopoldo, Northland, Rebeca, Sanne, Ian, Gogate, Jagadish, Greaves, Wayne, Isaacs, Randi

“…Background. Oropharyngeal candidiasis is the most common opportunistic infection among persons infected with human immunodeficiency virus (HIV). Use of some…”
Get full text

Weld Repair of Steam Turbine Rotor with 12 Cr Weld to Mitigate Corrosion Issues by Gowreesan, Vamadevan, Ario, Dhimas, Hanifa, Hepy, Greaves, Wayne

“…Weld repair of steam turbine rotors has become an acceptable practice to extend the life of rotors. Depending on the type of damage, the extent of weld repair…”
Get full text

HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug by PUTCHAROEN, Opass, SUN HEE LEE, HENRICH, Timothy J, ZIXIN HU, VANICHANAN, Jakapat, COAKLEY, Eoin, GREAVES, Wayne, GULICK, Roy M, KURITZKES, Daniel R, TSIBRIS, Athe M. N

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Characterization of Emergent HIV Resistance in Treatment-Naive Subjects Enrolled in a Vicriviroc Phase 2 Trial by McNicholas, Paul, Wei, Yi, Whitcomb, Jeannette, Greaves, Wayne, Black, Todd A., Tremblay, Cecile L., Strizki, Julie M.

“…Background. Vicriviroc is a C-C motif chemokine receptor 5 (CCR5) antagonist that is in clinical development for the treatment of human immunodeficiency virus…”
Get full text

Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection by Sherman, Kenneth E, Kang, Minhee, Sterling, Richard, Umbleja, Triin, Marks, Kristen, Kiser, Jennifer J, Alston-Smith, Beverly, Greaves, Wayne, Butt, Adeel A, The Actg Birth Study Team

“…AIM To evaluate efficacy/safety of hepatitis C virus(HCV) protease inhibitor boceprevir with pegylated interferon(PEG-IFN) alfa and weight-based ribavirin(RBV)…”
Get full text

Assessing Human Immunodeficiency Virus Type 1 Tropism: Comparison of Assays Using Replication-Competent Virus versus Plasma-Derived Pseudotyped Virions by Hosoya, Noriaki, Su, Zhaohui, Wilkin, Timothy, Gulick, Roy M, Flexner, Charles, Hughes, Michael D, Skolnik, Paul R, Giguel, Françoise, Greaves, Wayne L, Coakley, Eoin, Kuritzkes, Daniel R

“…Detection of CXCR4-using human immunodeficiency virus by the Trofile assay was compared to that by assays using virus isolates or replication-competent…”
Get full text

Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate by Greaves, Wayne, Wan, Hong, Yee, Ka Lai, Kandala, Bhargava, Vaddady, Pavan, Hwang, Carey

“…Doravirine is a non-nucleoside reverse transcriptase inhibitor approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently…”
Get full text

Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial by Kumar, Princy, Johnson, Margaret, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Wan, Hong, Xu, Zhi Jin, Morais, Cristiana, Sklar, Peter, Greaves, Wayne

“…In the primary analysis of the DRIVE-SHIFT trial, switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintained suppression of…”
Get full text

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial by Kumar, Princy, Johnson, Margaret, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Wan, Hong, Xu, Zhi Jin, Morais, Cristiana, Sklar, Peter, Greaves, Wayne

Get full text

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial by Johnson, Margaret, Kumar, Princy, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Mallolas, Josep, Zhou, Yan, Morais, Cristiana, Kumar, Sushma, Sklar, Peter, Hanna, George J, Hwang, Carey, Greaves, Wayne

“…BACKGROUND:Doravirine is a novel, nonnucleoside reverse transcriptase inhibitor with demonstrated efficacy in treatment-naive adults with HIV-1. METHODS:In…”
Get full text

Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes by Mocroft, Amanda, Pelchen-Matthews, Annegret, Hoy, Jennifer, Llibre, Josep M, Neesgaard, Bastian, Jaschinski, Nadine, Domingo, Pere, Rasmussen, Line Dahlerup, Günthard, Huldrych F, Surial, Bernard, Öllinger, Angela, Knappik, Michael, de Wit, Stephane, Wit, Ferdinand, Mussini, Cristina, Vehreschild, Joerg, Monforte, Antonella D'Arminio, Sonnerborg, Anders, Castagna, Antonella, Anne, Alain Volny, Vannappagari, Vani, Cohen, Cal, Greaves, Wayne, Wasmuth, Jan C, Spagnuolo, Vincenzo, Ryom, Lene

“…People with HIV and extensive antiretroviral exposure may have limited/exhausted treatment options (LExTO) due to resistance, comorbidities, or…”
Get full text